Amgen, Inc.: FDA regulatory profile

Amgen, Inc. appears in 5 indexed U.S. FDA records: 5 recall records, naming 5 distinct products. Latest dated event: a recall record dated 2026-07-01. Observations run 2026-07-01 to 2026-07-01, 5 dated records across 1 calendar year, busiest 2026 with 5. Recalls: 5 Class II (100%); 5 ongoing by lifecycle status, reported 2026-07-01; 5 with an FDA recall number, 5 with an initiation date, across 1 state, grouped into 1 FDA recall event. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. Recall records: Corlanor (ivabradine) tablets (D-0612-2026, Class II, 2026-07-01), Sensipar (cinacalcet) Tablets (D-0613-2026, Class II, 2026-07-01), Sensipar (cinacalcet) Tablets (D-0614-2026, Class II, 2026-07-01) and Corlanor (ivabradine) tablets (D-0615-2026, Class II, 2026-07-01). Recalling-firm addresses are recorded in CA. Its recall lines are grouped by the FDA into 1 event identifier: 99077. Distribution is recorded in the source as Nationwide within the United States.